Incorporation of Unnatural Amino Acids (UAAs) into Highly Complex Peptide Libraries

将非天然氨基酸 (UAA) 纳入高度复杂的肽库

• 批准号: 105697
• 金额: $ 40.21万
• 依托单位: ORBIT DISCOVERY LTD
• 依托单位国家: 英国
• 项目类别: Study
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=105697
• 关键词: Incorporation; Unnatural; Amino; Acids; UAAs

We are Orbit Discovery Ltd, a rapidly growing biotechnology company that works collaboratively with its partners to rapidly identify and characterise advanced peptide therapeutic drugs for a range of chronic diseases using a highly efficient in vitro screening technique.We want to develop synthetic biology technology for screening of potential drug targets with synthetic peptides possessing characteristics not possible in natural peptides. This means that we will make peptides that have a far greater application for a variety of diseases.This will enable more efficient production of stable peptide therapeutics, less likely to degrade when administered orally. Which essentially means, we will make better medicines, that can be taken orally, improving treatment effectiveness and making treatment more manageable.This project will enable Orbit to overcome limitations of structural constraints that limit target specificity, affinity and addressability and enable safer and faster drug development.

Orbit Discovery Ltd是一家快速发展的生物技术公司，与合作伙伴合作，利用高效的体外筛选技术快速鉴定和鉴定用于一系列慢性疾病的先进肽类治疗药物。我们希望开发合成生物学技术，利用合成肽筛选潜在的药物靶点，这些合成肽具有天然肽不可能具有的特性。这意味着我们将制造出对各种疾病有更大应用的肽，这将使更有效地生产稳定的肽治疗剂成为可能，口服时不太可能降解。这基本上意味着，我们将制造更好的药物，可以口服，提高治疗效果，使治疗更易于管理。该项目将使Orbit能够克服限制靶点特异性，亲和力和可寻址性的结构限制的局限性，并使药物开发更安全，更快。